BeiGene Announces Brukinsa™ (zanubrutinib) Is Approved in 50 Markets

BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
BeiGene and NewBridge Pharmaceuticals To Bring BRUKINSA to Patients in MENA Region, Following Approval for Previously Treated Mantle Cell Lymphoma in Kuwait, Bahrain and Qatar
BRUKINSA has Previously Been Approved by Regulatory Authorities in the U.S., China, the European Union, United Kingdom, Canada, Australia, South Korea and Switzerland
CAMBRIDGE, Mass.

Read the source article at biospace.com
2022-06-13 04:00:00